Journal Home > Volume 6 , Issue 1

In order to promote the clinical use of neural progenitor or precursor cells for treating neurological diseases and damage, we need to standardize culture procedures for these cells. The Chinese Association of Neurorestoratology put forward these standards for training operators, standardized use and management of materials and equipment, standardized isolation and culture for neural progenitor/precursor cells, and the standardized management in preservation, transport, and related safe operation procedures of the neural progenitors. These cultures and quality control standards also include the Good Manufacturing Practice environment, routine maintenance as well as the monitoring and reporting of the clinical-grade neural progenitor cells. The aim of these standards is to improve the therapeutic efficacy and minimize the possible side effects from lake of quality control.


menu
Abstract
Full text
Outline
About this article

Neurorestorative clinical application standards for the culture and quality control of neural progenitor/precursor cells (version 2017)

Show Author's information Shiqing Feng1,§Juan Xiao2,3,§Fabin Han4Lin Chen5Wenyong Gao2,3Gengsheng Mao2Hongyun Huang2,3
 International Science and Technology Cooperation Base of Spinal Cord Injury, Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
 Institute of Neurorestoratology, The General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing 100043, China
 The Institute for Tissue Engineering and Regenerative Medicine, Liaocheng University/Liaocheng People’s Hospital, Liaocheng 252000, China
 Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing 100040, China

§ These authors contributed equally to this work

Abstract

In order to promote the clinical use of neural progenitor or precursor cells for treating neurological diseases and damage, we need to standardize culture procedures for these cells. The Chinese Association of Neurorestoratology put forward these standards for training operators, standardized use and management of materials and equipment, standardized isolation and culture for neural progenitor/precursor cells, and the standardized management in preservation, transport, and related safe operation procedures of the neural progenitors. These cultures and quality control standards also include the Good Manufacturing Practice environment, routine maintenance as well as the monitoring and reporting of the clinical-grade neural progenitor cells. The aim of these standards is to improve the therapeutic efficacy and minimize the possible side effects from lake of quality control.

Keywords: neurorestoratology, cell culture, quality control, standardization, neural progenitor cells, neural precursor cells

References(26)

[1]
Richards LJ, Kilpatrick TJ, Banlett PF. De novo generation of neuronal cells from the adult mouse brain. Proc Natl Acad Sci USA. 1992, 89(18):8591-8595.
[2]
McKay R. Stem cells in the central nervous system. Science. 1997, 276(5309):66-71.
[3]
Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999, 97(6):703-716.
[4]
Cai Z, Yan Y, Tang Y, et al. Neural stem cells: promising therapy for Alzheimer’s disease. Chin Bull Life Sci. 2008, 20(1):90-94.
[5]
Zhao N, Zhong C, Hong Z. Neurogenesis in the adult subventricular zone. Chin J Clin Neurosci. 2007, 15(01):96-99.
[6]
Davis AA, Temple S. A self-renewing multipotential stem cell in embryonic rat cerebral cortex. Nature. 1994, 372(6503):263-266.
[7]
Jiang X, Wang H, Chen L, et al. Culture and identification of neural stem/progenitor cells from human embryonic subependymal zone by adherent method. Prog Anat Sci. 2011, 16(4):307-310.
[8]
Gao W, Jiang X, Xiao J, et al. The cultivation, cryopreservation and identification of human embryonic striatum tissue neural stem/progenitor cells. Prog Anat Sci. 2015, (6):642-644.
[9]
Bao J, Huang H. Definition of neural stem cells. Chin J Neurosurg. 2008, 24(10):793-796.
[10]
Moviglia GA, Moviglia-Brandolino MT, Varela GS, et al. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 2012, 21(Suppl 1):S57-S63.
[11]
Riley J, Glass J, Feldman EL, et al. Intraspinal stem cell transplantation in ALS: a Phase I trial, cervical microinjection and final surgical safety outcomes. Neurosurgery. 2012, 71(2):405-416.
[12]
Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014, 75(3):363-373.
[13]
Mazzini L, Gelati M, Profico DC, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015, 13:17.
[14]
Nelson PT, Kondziolka D, Wechsler L, et al. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol. 2002, 160(4):1201-1206.
[15]
Luan Z, Liu WP, Qu SQ, et al. Treatment of newborns with severe injured brain with transplantation of human neural precursor cells. Zhonghua Er Ke Za Zhi. 2011, 49(6):445-449.
[16]
Chen L, Xi H, Huang H, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013, 22(Suppl 1):S83-S91.
[17]
Xi H, Chen L, Huang H, et al. Preliminary report of multiple cell therapy for patients with multiple system atrophy. Cell Transplant. 2013, 22(Suppl 1):S93-S99.
[18]
Zhou Q, Zhang SZ, Xu RX, Xu K. Neural stem cell transplantation and postoperative management: report of 70 cases. Di Yi Jun Yi Da Xue Xue Bao. 2004, 24(10):1207-1209.
[19]
Guzman R, Schubert M, Keller-Lang D, Huhn SL, Curt A. Human neural stem cell transplantation in chronic SCI: interim results of a Phase I/II trial. Neurosurgery. 2013, 60(Suppl 1):185.
[20]
Shin JC, Kim KN, Yoo J, et al. Clinical trial of human fetal brain-derived neural stem/progenitor cell transplantation in patients with traumatic cervical spinal cord injury. Neural Plast. 2015, 2015:630932.
[21]
Curtis E, Gabel BC, Marsala M, Ciacci JD. A phase I, open- label, single-site, safety study of human spinal cord-derived neural stem cell transplantation for the treatment of chronic spinal cord injury. Neurosurgery. 2016, 63(Suppl 1):168-169.
[22]
Ren Y, Tian G, Wang H, et al. Quality specification of human embryo olfactory ensheathing cells from olfactory bulb. Chin J Tissue Eng Res. 2008, 12(16):3156-3157.
[23]
Chinese Medical Doctor Association of Neurorestoratology Professional Committee; Chinese Branch of the International Association of Neurorestoratology. Clinical cell therapy guidelines for neurorestoration (China version 2015). Chin J Cell Stem Cell. 2016, 6:1-7.
[24]
Huang H, Chen L, Zou Q, et al. Clinical cell therapy guidelines for neurorestoration (China version 2016). J Neurorestoratol. 2017, 5:39-46.
[25]
Jiang X, Xiao J, Ren Y et al. The influence of 4 degree centigrade conservation on cells activity of rats’ olfactory bulbs derived olfactory ensheathing cells. Prog Anat Sci. 2011, 17(5):424-427.
[26]
Gobbel GT, Kondziolka D, Fellows-Mayle W, Uram M. Cellular transplantation for the nervous system: impact of time after preparation on cell viability and survival. J Neurosurg. 2010, 113(3):666-672.
Publication history
Copyright
Rights and permissions

Publication history

Received: 01 August 2017
Accepted: 29 May 2018
Published: 09 November 2018
Issue date: December 2018

Copyright

© The authors 2018.

Rights and permissions

© The authors 2018. This article is published with open access at http://jnr.tsinghuajournals.com

Return